We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Effective Minimally-Invasive Option for Treating Bowel Incontinence

By HospiMedica International staff writers
Posted on 09 Sep 2009
A new therapy delivers radiofrequency (RF) energy to the muscles of the anal canal, producing better bowel control and reducing the symptoms of incontinence.

Secca therapy is an outpatient procedure that takes approximately 45 minutes. More...
It is performed in an endoscopy suite or ambulatory surgery unit, with the patient under general anesthesia (GA) or conscious sedation. During the procedure, RF at a frequency of 465 kHz enters the anal muscle tissue via an electrode, causing water molecules in the adjacent tissue to vibrate at the molecular level, generating heat.

As a result, multiple small tissue contractions are formed, and this causes the significant restoration of function to the anal sphincter. The delivery of RF energy is controlled using temperature feedback via temperature sensors both in the needle electrode and at the base of the needle in the Secca catheter. A control module regulates the four-channel RF energy generator via constant monitoring of temperature and impedance, enabling precise energy delivery, and an interactive graphics screen displays real-time progress. RF power is delivered at a level needed to achieve--but not exceed--the target temperature of 85 oC. A disposable handpiece is used for direct visualization and device positioning, and integrated ports deliver chilled water to the mucosa while deeper tissue is treated. Secca therapy was developed by Mederi Therapeutics (Greenwich, CT, USA).

"This innovative treatment bridges the gap between often unsuccessful conservative measures, such as diet modification and biofeedback, and expensive and disfiguring surgical treatment,” said Will Rutan, CEO of Mederi. "The effect of bowel incontinence on quality of life is devastating, so the overwhelmingly positive response to the release of the Secca system is not surprising.”

Patients can return home approximately one to two hours after the procedure and typically resume normal activities within several days. In clinical trials, as many as 8 out of 10 patients had a positive clinical response to the therapy and showed significant improvement in quality of life scores. Additionally, recent clinical studies have shown symptom relief lasting as long as five years.

Related Links:

Mederi Therapeutics



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.